vertex - Search News

Vertex Stock Jumps

MarketWatch · 3h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

Wall Street Journal · 2h

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA Approval

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades](

BioPharma Dive · 13h

Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

Vertex, Casgevy and England

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) gene therapy to treat a severe form of sickle cell disease (SCD).

Business Insider · 5h

Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with

The Bakersfield Californian · 6h

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).

37mon MSN

These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Visa, Deckers, Atlassian, Vertex, and More

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

26m

Vertex Pharmaceuticals price target lowered to $320 from $325 at Baird

Baird lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $320 from $325 and keeps an Underperform rating on the shares. The ...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

5don MSN

Is Vertex Pharmaceuticals Stock a Buy in 2025?

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

1h

Vertex Pharmaceuticals’ JOURNA VX: Navigating Market Challenges Despite Promising Financial Outlook

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today.Invest with Confidence: Follow ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results